Form 4: Karyopharm Executive Reports Stock Transactions

Karyopharm Therapeutics' EVP, Chief Development Officer, Stuart Poulton, reported the vesting of performance-based restricted stock units and a subsequent tax-related sale of common stock.

Summary

• Stuart Poulton, EVP, Chief Development Officer of Karyopharm Therapeutics Inc., reported changes in his beneficial ownership of common stock.
• On September 12, 2025, 888 shares of common stock underlying performance-based restricted stock units (PSUs) vested.
• These PSUs were granted in February 2023 and earned based on the achievement of a clinical milestone: complete enrollment in the Company's Phase 3 SENTRY trial, as certified by the Compensation Committee.
• Following this vesting, Poulton's beneficial ownership increased to 28,111 shares.
• On September 15, 2025, Poulton sold 401 shares of common stock at a price of $6.43 per share.
• This sale was executed pursuant to a durable automatic sale instruction plan adopted on May 18, 2022, and was specifically to satisfy withholding tax liability incurred upon the PSU vesting, not a discretionary trade.
• After the sale, Poulton's beneficial ownership stands at 27,710 shares.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions (vesting of PSUs and a non-discretionary tax-related sale) which are neutral in sentiment. The underlying achievement of a clinical milestone is positive, but the filing itself is purely transactional.

Positives

• The vesting of 888 performance-based restricted stock units indicates the successful achievement of a clinical milestone, specifically complete enrollment in the Phase 3 SENTRY trial, which is a positive operational development for Karyopharm Therapeutics Inc.

Negatives

• A reduction of 401 shares in direct beneficial ownership occurred due to a tax-related sale, although this was non-discretionary.

Future Outlook

The filing does not provide explicit forward-looking statements or guidance beyond the achievement of a past clinical milestone (SENTRY trial enrollment) that led to PSU vesting.

Management Comments

• The transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022.
• The sale represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs.
• The sale does not represent a discretionary trade by the reporting person.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common for executives in publicly traded companies, particularly in the biotech sector where performance-based compensation tied to clinical milestones is prevalent. The underlying event, the achievement of complete enrollment in a Phase 3 trial, is a significant operational step in drug development, indicating progress for Karyopharm Therapeutics within the pharmaceutical industry.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding executive stock ownership changes, which are routine and not indicative of a change in company fundamentals. The underlying milestone (SENTRY trial enrollment) is a positive for future drug development.

Next Steps

• Continued progress and eventual results from the Phase 3 SENTRY trial are implied following its complete enrollment.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions, specifically the vesting of performance-based restricted stock units and a subsequent non-discretionary sale to cover tax liabilities. Such transactions do not typically signal a change in the company's fundamental outlook or warrant a strong investment action. The underlying achievement of a clinical milestone (SENTRY trial enrollment) is positive, but the filing itself is purely a disclosure of compensation-related stock movements.

Keywords

Karyopharm Therapeutics, KPTI, Stuart Poulton, Form 4, Insider Transaction, Restricted Stock Units, PSU, SENTRY trial, Clinical Milestone, Stock Sale